The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.
The 5-mg dose of oxybutynin reduced the frequency and severity of hot flashes in men with prostate cancer undergoing treatment with androgen-deprivation therapy compared with placebo.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果